Loading...
Loading...
AMPH| Name | Value |
|---|---|
| Revenues | 188.8M |
| Cost of Revenue | 86.9M |
| Gross Profit | 101.9M |
| Operating Expense | 44.9M |
| Operating I/L | 57.0M |
| Other Income/Expense | -9.4M |
| Interest Income | 2.4M |
| Pretax | 47.7M |
| Income Tax Expense | 7.3M |
| Net Income/Loss | 40.4M |
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that develops, manufactures, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company's revenue is generated through two segments, Finished Pharmaceutical Products and API. Its product portfolio includes a range of medications such as Primatene Mist, Enoxaparin, Naloxone, Glucagon, Cortrosyn, Amphadase, Epinephrine injection, lidocaine products, phytonadione injection, emergency syringe products, morphine injection, lorazepam injection, neostigmine methylsulfate injection, Isoproterenol hydrochloride injection, and insulin active pharmaceutical ingredients (API). The company serves hospitals, care facilities, clinics, and doctors' offices.
